João Mendes. Joanne Alves e Ênio Simas conversam sobre 7 armadilhas na dor lombar.

Vote no TdC no Prêmio Melhores Podcasts do Brasil. Estamos na categoria Ciência https://www.premiompb.com.br/

Referências:

1. https://amdg.wa.gov/Files/AssessmentTools/5-Keele_STarT_Back9_item-7.pdf

2. Chou, Roger, and Paul Shekelle. “Will this patient develop persistent disabling low back pain?.” JAMA vol. 303,13 (2010): 1295-302. doi:10.1001/jama.2010.344

3. Stevans, Joel M et al. “Risk Factors Associated With Transition From Acute to Chronic Low Back Pain in US Patients Seeking Primary Care.” JAMA network open vol. 4,2 e2037371. 1 Feb. 2021, doi:10.1001/jamanetworkopen.2020.37371

4. Suri, Pradeep et al. “Predictive Validity of the STarT Back Tool for Risk of Persistent Disabling Back Pain in a U.S. Primary Care Setting.” Archives of physical medicine and rehabilitation vol. 99,8 (2018): 1533-1539.e2. doi:10.1016/j.apmr.2018.02.016

5. Samanta, Jo et al. “10-minute consultation: chronic low back pain.” BMJ (Clinical research ed.) vol. 326,7388 (2003): 535. doi:10.1136/bmj.326.7388.535

6. Gomes, Luís Antunes et al. “A Stratified Approach for Managing Patients With Low Back Pain in Primary Care (SPLIT Program): A Before-and-After Study.” Annals of family medicine vol. 22,3 (2024): 195-202. doi:10.1370/afm.3104

7. Richmond, Helen et al. “The Effectiveness of Cognitive Behavioural Treatment for Non-Specific Low Back Pain: A Systematic Review and Meta-Analysis.” PloS one vol. 10,8 e0134192. 5 Aug. 2015, doi:10.1371/journal.pone.0134192

8. Chou, Roger et al. “Nonpharmacologic therapies for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline.” Annals of internal medicine vol. 147,7 (2007): 492-504. doi:10.7326/0003-4819-147-7-200710020-00007

9. Qaseem, Amir et al. “Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians.” Annals of internal medicine vol. 166,7 (2017): 514-530. doi:10.7326/M16-2367

10. Flynn, Diane M. “Chronic Musculoskeletal Pain: Nonpharmacologic, Noninvasive Treatments.” American family physician vol. 102,8 (2020): 465-477.

11. Chou, Roger et al. “Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society.” Annals of internal medicine vol. 147,7 (2007): 478-91. doi:10.7326/0003-4819-147-7-200710020-00006

12. Vitoula, Kristallia et al. “Behavioral Therapy Approaches for the Management of Low Back Pain: An Up-To-Date Systematic Review.” Pain and therapy vol. 7,1 (2018): 1-12. doi:10.1007/s40122-018-0099-4

13. Deyo, R A, and J N Weinstein. “Low back pain.” The New England journal of medicine vol. 344,5 (2001): 363-70. doi:10.1056/NEJM200102013440508

14. van Middelkoop, Marienke et al. “Exercise therapy for chronic nonspecific low-back pain.” Best practice & research. Clinical rheumatology vol. 24,2 (2010): 193-204. doi:10.1016/j.berh.2010.01.002

Fred Amorim apresenta caso clínico de hemoptise para Kaue Malpighi e Lucca Cirillo.

----------------------------------------------------------------

🚨 www.tadeclinicagem.com.br/guia - Conheça o Guia TdC com 7 dias grátis 🚨 🔴 Junte-se aos mais de 3.000 assinantes. Assine o Guia, ganhe tempo e atualize-se sem esforço. 🟠 Um serviço de revisão e atualização continuados em clínica médica. A informação que você precisa, do jeito que você prefere. 📚 Confira agora mesmo a edição aberta do Guia TdC sobre a nova diretriz de Insuficiência Cardíaca (IC) da American Heart Association (AHA): https://www.tadeclinicagem.com.br/guia/2/diretriz-de-insuficiencia-cardiaca-aha-2022/. ----------------------------------------------------------------

Referências:

1. Atchinson PRA, Hatton CJ, Roginski MA, Backer ED, Long B, Lentz SA. The emergency department evaluation and management of massive hemoptysis. Am J Emerg Med. 2021 Dec;50:148-155. doi: 10.1016/j.ajem.2021.07.041. Epub 2021 Jul 27. PMID: 34365064.

2. Ittrich H, Bockhorn M, Klose H, Simon M. The Diagnosis and Treatment of Hemoptysis. Dtsch Arztebl Int. 2017 Jun 5;114(21):371-381. doi: 10.3238/arztebl.2017.0371. PMID: 28625277; PMCID: PMC5478790.

3. Charya AV, Holden VK, Pickering EM. Management of life-threatening hemoptysis in the ICU. J Thorac Dis. 2021 Aug;13(8):5139-5158. doi: 10.21037/jtd-19-3991. PMID: 34527355; PMCID: PMC8411133.

4. Casey JD, Englert JA, Katz JT, Miller AL, Loscalzo J. An Unexpected Expectoration. N Engl J Med. 2018 Mar 1;378(9):853-858. doi: 10.1056/NEJMcps1711048. PMID: 29490174.

5. Charya AV, Holden VK, Pickering EM. Management of life-threatening hemoptysis in the ICU. J Thorac Dis. 2021 Aug;13(8):5139-5158. doi: 10.21037/jtd-19-3991. PMID: 34527355; PMCID: PMC8411133.

6. McGuinness G, Beacher JR, Harkin TJ, Garay SM, Rom WN, Naidich DP. Hemoptysis: prospective high-resolution CT/bronchoscopic correlation. Chest. 1994 Apr;105(4):1155-62. doi: 10.1378/chest.105.4.1155. PMID: 8162743.

7. Haponik EF, Chin R. Hemoptysis: clinicians' perspectives. Chest. 1990 Feb;97(2):469-75. doi: 10.1378/chest.97.2.469. PMID: 2298074.

8. Herth F, Ernst A, Becker HD. Long-term outcome and lung cancer incidence in patients with hemoptysis of unknown origin. Chest. 2001 Nov;120(5):1592-4. doi: 10.1378/chest.120.5.1592. PMID: 11713139.

9. Atchinson, Patricia Ruth A et al. “The emergency department evaluation and management of massive hemoptysis.” The American journal of emergency medicine vol. 50 (2021): 148-155. doi:10.1016/j.ajem.2021.07.041

10. Singhal, Rajat et al. “Society of Chest Imaging and Interventions Consensus Guidelines for the Interventional Radiology Management of Hemoptysis.” The Indian journal of radiology & imaging vol. 33,3 361-372. 10 Apr. 2023, doi:10.1055/s-0043-1762552

Raphael e Marcela convidam novamente Nathalie Santana para falar sobre tratamento do hipertiroidismo em 4 clinicagens: como escolher o melhor tratamento? como controlar os sintomas? como prescrever drogas antitireoidianas? como monitorar o paciente?

Use o cupom TDC2024 para assinar o HITT do Medcof e ganhe um cupom de 6 meses gratuitos do Guia TdC!

https://hiit.grupomedcof.com.br

Minutagem

(00:00) Apresentação e sumarização

(04:05) Hipertireoidismo x tireotoxicose

(07:10) Como escolher o melhor tratamento

(17:55) Como controlar os sintomas da doença

(21:40) Como prescrever as drogas antitireoidianas

(31:33) Como monitorar o paciente em uso de drogas antitireoidianas

(43:33) Encerramento e salves

Referências:

1. Azizi, F et al. “Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine.” European journal of endocrinology vol. 152,5 (2005): 695-701. doi:10.1530/eje.1.01904

2. Villagelin, Danilo et al. “Outcomes in Relapsed Graves' Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment.” Thyroid : official journal of the American Thyroid Association vol. 25,12 (2015): 1282-90. doi:10.1089/thy.2015.0195

3. Kahaly, George J et al. “2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.” European thyroid journal vol. 7,4 (2018): 167-186. doi:10.1159/000490384

4. Villagelin, Danilo et al. “A 2023 International Survey of Clinical Practice Patterns in the Management of Graves' Disease: A Decade of Change.” The Journal of clinical endocrinology and metabolism, dgae222. 5 Apr. 2024, doi:10.1210/clinem/dgae222

5. Ross, Douglas S et al. “2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.” Thyroid : official journal of the American Thyroid Association vol. 26,10 (2016): 1343-1421. doi:10.1089/thy.2016.0229

6. Shalaby M, Hadedeya D, Toraih EA, et al. Predictive factors of radioiodine therapy failure in Graves' Disease: A meta-analysis. Am J Surg. 2022;223(2):287-296. doi:10.1016/j.amjsurg.2021.03.068

7. Carella, C et al. “Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.” Thyroid : official journal of the American Thyroid Association vol. 16,3 (2006): 295-302. doi:10.1089/thy.2006.16.295 8. Struja T, Kaeslin M, Boesiger F, et al. External validation of the GREAT score to predict relapse risk in Graves' disease: results from a multicenter, retrospective study with 741 patients. Eur J Endocrinol. 2017;176(4):413-419. doi:10.1530/EJE-16-0986

9. Park SY, Kim BH, Kim M, et al. The longer the antithyroid drug is used, the lower the relapse rate in Graves' disease: a retrospective multicenter cohort study in Korea. Endocrine. 2021;74(1):120-127. doi:10.1007/s12020-021-02725-x

10. Azizi F, Amouzegar A, Tohidi M, et al. Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves' Disease: Results of a Randomized Clinical Trial. Thyroid. 2019;29(9):1192-1200. doi:10.1089/thy.2019.0180

11. Chaker L, Cooper DS, Walsh JP, Peeters RP. Hyperthyroidism. Lancet. 2024;403(10428):768-780. doi:10.1016/S0140-6736(23)02016-0

12. Lee SY, Pearce EN. Hyperthyroidism: A Review. JAMA. 2023;330(15):1472-1483. doi:10.1001/jama.2023.19052

13. https://www.tadeclinicagem.com.br/guia/146/tempestade-tireotoxica/